![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JE Leysen, W Gommeren, P Van Gompel, J Wynants, PF Janssen and PM Laduron
In vitro and in vivo receptor-binding properties of the new serotonin antagonist, ritanserin, are reported. In in vitro binding assays, ritanserin shows high affinity binding to serotonin-S2 sites in rat frontal cortex tissue: IC50 = 0.9 nM without drug preincubation and 0.3 nM with 30-min drug preincubation; IC50 values for histamine-H1, dopamine-D2, and adrenergic-alpha 1 and -alpha 2 sites were 39-, 77-, 107-, and 166-fold higher, and at up to 1 microM, the drug did not bind to serotonin-S1 sites. In in vitro assays, ritanserin dissociated very slowly from serotonin-S2 (t1/2 = 160 min) and histamine-H1 sites (t1/2 = 77 min) and rapidly from dopamine-D2 sites (t1/2 = 11 min). Half- times of dissociation from adrenergic-alpha 1 and -alpha 2 sites were 18 and 26 min. The inhibition by ritanserin of [3H]ketanserin binding was found to be partially noncompetitive and the inhibitory potency increased with drug preincubation. Due to the slow dissociation of ritanserin from the serotonin-S2 sites, the drug cannot be displaced completely by [3H]ketanserin. In contrast, inhibition by ritanserin of [3H]haloperidol binding to dopamine-D2 sites in rat striatum was fully competitive, in agreement with the rapid dissociation of the drug from the latter sites. In ex vivo binding assays using brain areas of rats and guinea pigs treated subcutaneously with ritanserin, occupation of serotonin-S2 sites was observed at very low dosage (50% occupation at 0.08-0.1 mg/kg) and sites remained occupied during a prolonged time period (greater than 70% occupation up to 48 hr after 2.5 mg/kg ritanserin). Histamine-H1 receptor sites in guinea pig cerebellum became occupied at dosages 25-fold higher than the dosage producing occupation of frontal cortical serotonin-S2 sites. Dopamine-D2 sites in rat striatum and cortical adrenergic-alpha 1 sites became only slightly occupied (less than 20%) at higher dosages and the effect was not dose- dependent. Adrenergic-alpha 2 sites were not occupied up to doses of 160 mg/kg given subcutaneously. In vivo binding assays using [3H]spiperone confirmed the occupation of frontal cortical serotonin-S2 sites following low dosage of ritanserin and a minor occupation of striatal dopamine-D2 sites. Levels of dopamine and serotonin and their metabolites remained unchanged in brain areas of rats orally treated with ritanserin up to dosages of 40 mg/kg. At 160 mg/kg, there seemed to be a slight reduction in dopamine and serotonin content.(ABSTRACT TRUNCATED AT 400 WORDS)
This article has been cited by other articles:
|
|
 |
|
  Y. Wang, W. Beck, R. Deppisch, S. M. Marshall, N. A. Hoenich, and M. G. Thompson Differential effects of dialysis and ultrafiltrate from individuals with CKD, with or without diabetes, on platelet phosphatidylserine externalization Am J Physiol Renal Physiol, January 1, 2008; 294(1): F220 - F228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, W. Beck, R. Deppisch, S. M. Marshall, N. A. Hoenich, and M. G. Thompson Advanced glycation end products elicit externalization of phosphatidylserine in a subpopulation of platelets via 5-HT2A/2C receptors Am J Physiol Cell Physiol, July 1, 2007; 293(1): C328 - C336. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Vanover, D. M. Weiner, M. Makhay, I. Veinbergs, L. R. Gardell, J. Lameh, A. L. Del Tredici, F. Piu, H. H. Schiffer, T. R. Ott, et al. Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 910 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Popa, C. Lena, V. Fabre, C. Prenat, J. Gingrich, P. Escourrou, M. Hamon, and J. Adrien Contribution of 5-HT2 Receptor Subtypes to Sleep-Wakefulness and Respiratory Control, and Functional Adaptations in Knock-Out Mice Lacking 5-HT2A Receptors J. Neurosci., December 7, 2005; 25(49): 11231 - 11238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, K. J. Damjanoska, G. A. Carrasco, B. Dudas, D. N. D'Souza, J. Tetzlaff, F. Garcia, N. R. S. Hanley, K. Scripathirathan, B. R. Petersen, et al. Evidence That 5-HT2A Receptors in the Hypothalamic Paraventricular Nucleus Mediate Neuroendocrine Responses to (-)DOI J. Neurosci., November 1, 2002; 22(21): 9635 - 9642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Schrott, M. I. Baumgart, X. Zhang, and S. B. Sparber Prenatal Opiate Withdrawal Activates the Chick Embryo Hypothalamic-Pituitary-Adrenal Axis and Dilates Vitelline Blood Vessels via Serotonin2 Receptors J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 257 - 264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Ehlen, G. H. Grossman, and J. D. Glass In Vivo Resetting of the Hamster Circadian Clock by 5-HT7 Receptors in the Suprachiasmatic Nucleus J. Neurosci., July 15, 2001; 21(14): 5351 - 5357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. D. Van de Kar, A. Javed, Y. Zhang, F. Serres, D. K. Raap, and T. S. Gray 5-HT2A Receptors Stimulate ACTH, Corticosterone, Oxytocin, Renin, and Prolactin Release and Activate Hypothalamic CRF and Oxytocin-Expressing Cells J. Neurosci., May 15, 2001; 21(10): 3572 - 3579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Wiesbeck, H.-G. Weijers, J. Chick, and J. Boening THE EFFECTS OF RITANSERIN ON MOOD, SLEEP, VIGILANCE, CLINICAL IMPRESSION, AND SOCIAL FUNCTIONING IN ALCOHOL-DEPENDENT INDIVIDUALS Alcohol Alcohol., July 1, 2000; 35(4): 384 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Okuyama, S. Chaki, R. Yoshikawa, Y. Suzuki, S.-I. Ogawa, Y. Imagawa, N. Kawashima, Y. Ikeda, T. Kumagai, A. Nakazato, et al. In Vitro and In Vivo Characterization of the Dopamine D4 Receptor, Serotonin 5-HT2A Receptor and Alpha-1 Adrenoceptor Antagonist (R)-(+)-2-Amino-4-(4-Fluorophenyl)- 5-[1-[4-(4-Fluorophenyl)-4-Oxobutyl]Pyrrolidin-3-yl]Thiazole (NRA0045) J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 56 - 63. [Abstract] [Full Text]
|
|
|
|
|
|
K. Minami, M. Minami, and R. A. Harris J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1136 - 1143. [Abstract] [Full Text]
|
|
|
|
|
|
J.-P. Valentin, S. Vieu, F. Bertolino, P. Fauré, and G. W. John Differential Involvement of Serotonin 2A/C and Thromboxane A2/Prostanoid Receptors in High- vs. Low-Shear Rate Arterial Thrombosis in Rabbits J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 761 - 769. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. M. Dursun and S. L. Handley Complex of rapid movements and vocalization induced by RX336-M in mice: possible relevance to Tourette's syndrome J Psychopharmacol, January 1, 1994; 8(1): 27 - 31. [Abstract] [PDF]
|
|
|
|
|
|
H. J. Cassaday, H. Hodges, and J. A. Gray The effects of ritanserin, RU 24969 and 8-OH-DPAT on latent inhibition in the rat J Psychopharmacol, January 1, 1993; 7(1_suppl): 63 - 71. [Abstract] [PDF]
|
|
|
|
|
|
E.A. Audi, J.C. de Aguiar, and F.G. Graeff Mediation by serotonin of the antiaversive effect of zimelidine and propranolol injected into the dorsal midbrain central grey J Psychopharmacol, January 1, 1988; 2(1): 26 - 32. [Abstract] [PDF]
|
|
|
|
|
|
S. V. Vellucci, P.J. Martin, and B. J. Everitt The discriminative stimulus produced by pentylenetetrazol: effects of systemic anxiolytics and anxiogenics, aggressive defeat and midazolam or muscimol infused into the amygdala J Psychopharmacol, January 1, 1988; 2(2): 80 - 93. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
